(Q43948653)

English

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

based on heuristic

inferred from title

author name string

Neele SJ

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Evertz R

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

De Valk-De Roo G

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Roos JC

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Netelenbos JC

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

publication date

1 April 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

599-603

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with Tibolone

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term postmenopausal hormone replacement therapy effects on bone mass: differences between surgical and spontaneous patients

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Raloxifene: a review of its use in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen and calcium supplement use among Japanese-American women: effects upon bone loss when used singly and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect on bone of withdrawal of oestrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokines, bone remodeling, and estrogen deficiency: a 1998 update

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone response to termination of oestrogen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of postmenopausal osteoporosis with transdermal estrogen

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Fracture protection provided by long-term estrogen treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900706-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S8756-3282(01)00706-2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43948653&oldid=2104584281"